{"denoms":[{"counts":[{"groupId":"BG000","value":"346"},{"groupId":"BG001","value":"346"},{"groupId":"BG002","value":"692"}],"units":"Participants"}],"groups":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nComputed Tomography: Correlative studies\n\nPaclitaxel: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"BG000","title":"Arm I (Adjuvant Chemotherapy Suboptimally Debulked)"},{"description":"Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nComputed Tomography: Correlative studies\n\nPaclitaxel: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"BG001","title":"Arm II (Neoadjuvant Chemotherapy)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"214"},{"groupId":"BG001","value":"217"},{"groupId":"BG002","value":"431"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"261"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"346"},{"groupId":"BG001","value":"346"},{"groupId":"BG002","value":"692"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"345"},{"groupId":"BG001","value":"345"},{"groupId":"BG002","value":"690"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"South Korea"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"Newly diagnosed women with high-risk early stage or advanced stage epithelial ovarian cancer."}